Optimizing management of Crohn's disease within a project management framework: Results of a pilot study

Inflammatory Bowel Diseases

Volumn 18, Issue 2, 2012, Pages 254-260

  Keefer, Laurie ^a   Doerfler, Bethany ^a   Artz, Caroline ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Crohn's disease; inflammatory bowel disease; project management; self management

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE COURSE; DISTRESS SYNDROME; FEMALE; HUMAN; IBD SELF EFFICACY SCALE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MALE; MEDICATION ADHERENCE SCALE; PERCEIVED STRESS QUESTIONNAIRE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE;

ADULT; BEHAVIOR THERAPY; CROHN DISEASE; DISEASE MANAGEMENT; FEMALE; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84855918457     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21679     Document Type: Article

References (84)

1. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med. 2008; 50: 1261-1272.
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010; 105: 289-297.
3. Cohen R,. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002; 16: 1603-1609.
4. Irvine E,. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol. 1997; 92: 18S-24S.
5. Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1575-1584.
6. Larsson K, Loof L, Ronnblom A, et al. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res. 2008; 64: 139-148.
7. Marri S, Buchman AL,. The education and employment status of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 171-177. (Pubitemid 40711222)
8. Bernstein CN,. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2002; 4: 513-516.
9. Sandborn W, Feagan BG, Lichtenstein GR,. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007; 26: 987-1003. (Pubitemid 47416299)
10. Burgmann T, Rawsthorne P, Bernstein CN,. Predictors of complementary and alternative medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use. Am J Gastroenterol. 2004; 99: 889-893. (Pubitemid 39090219)
11. Janke K, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 272-286. (Pubitemid 40439682)
12. Longobardi T, Jacobs P, Lieling W, et al. Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. Am J Gastroenterol. 2003; 98: 844-849. (Pubitemid 36576312)
13. de Rooy E, Toner BB, Maunder RG, et al. Concerns of patients with inflammatory bowel disease: Results from a clinical population. Am J Gastroenterol. 2001; 96: 1816-1821.
14. Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn's disease. Am J Gastroenterol. 2008; 103: 154-161.
15. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005; 39: 390-395. (Pubitemid 40548076)
16. Rogala L, Miller N, Graff LA, et al. Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 526-535. (Pubitemid 351571833)
17. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010; 31: 1296-1309.
18. Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010; 16: 1912-1921.
19. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010; 31: 1296-1309.
20. Lutgens M, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009; 101: 161-165.
21. Beaugerie L SH, Seksik P,. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig Dis. 2009; 27: 375-381.
22. Moscandrew M MU, Kane S,. General health maintenance in IBD. Inflamm Bowel Dis. 2009; 15: 1399-1409.
23. Zisman T, Rubin DT,. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 2662-2669.
24. Chan EP, Lichtenstein GR,. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2006; 35: 675-712. (Pubitemid 44314185)
25. Kane S, Cohen RD, Aikens JE, et al. Predictors of non-compliance with mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2932.
26. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009; 29: 247-257.
27. Kane S,. Medication adherence and the physician-patient relationship. Am J Gastroenterol. 2002; 97: 1853.
28. Kane S,. Is non-adherence to blame? Inflamm Bowel Dis. 2005; 11: 705.
29. Kane S, Dixon L,. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006; 24: 1099-1103. (Pubitemid 44386535)
30. Kane S, Shaya F,. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008; 53: 1020-1024. (Pubitemid 351379831)
31. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 577-585.
32. Kane SV,. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs. 2008; 68: 2601-2609.
33. Kane SV, Chao J, Mulani PM,. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009; 26: 936-946.
34. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 1417-1426. (Pubitemid 46976288)
35. Shale M, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191-203.
36. Sewitch M, Abrahamowicz M, Barkun A, et al. Patient non-adherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 1535-1544. (Pubitemid 36875345)
37. Lakatos PL,. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol. 2009; 15: 4234-4239.
38. Moser G, Maeir-Dobersberger T, Vogelsang H, et al. Inflammatory bowel disease: patients beliefs about the etiology of their diseaseâ a controlled study. Psychosom Med. 1993; 55: 131.
39. Bitton A, Sewitch M, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003; 98: 2203-2208. (Pubitemid 37305360)
40. Bernstein CN, Walker JR, Graff LA,. On studying the connection between stress and IBD. Am J Gastroenterol. 2006; 101: 782-785.
41. Keefer L, Keshavarzian A, Mutlu E,. Reconsidering the methodology of "stress" research in inflammatory bowel disease. J Crohn's Colitis. 2008; 2: 193-201.
42. Mawdsley JE, Macey MG, Feakins RM, et al. The effect of acute psychological stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology. 2006; 131: 410-419. (Pubitemid 44142453)
43. Mawdsley J, Rampton DS,. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005; 54: 1481-1491. (Pubitemid 41375207)
44. Maunder R,. Evidence that stress contributes to inflammatory bowel disease: evaluation, synthesis and future directions. Inflamm Bowel Dis. 2005; 11: 600-608. (Pubitemid 40826349)
45. Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am J Gastroenterol. 1994; 89: 1219-1225. (Pubitemid 24245799)
46. Graff LA, Walker JR, Clara I, et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol. 2009; 104: 2959-2969.
47. Graff LA, Walker JR, Bernstein CN,. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009; 15: 1105-1118.
48. Jones M, Wessinger S, Crowell MD,. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 474-481.
49. van den lejk L, Vlachonikolis IG, Munkholm P, et al. The role of quality of care in health-related quality of life in patients with IBD. Inflamm Bowel Dis. 2004; 10: 392-398. (Pubitemid 39036127)
50. Baars JE, Markus T, Kuipers EJ, et al. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion. 2010; 81: 113-119.
51. Dupuis M, Marshall JK, Hayes SM, et al. Assessing the educational needs of Canadian gastroenterologists and gastroenterology nurses: challenges to optimal care in Crohn's Disease. Can J Gastroenterol. 2009; 23: 805-810.
52. Kane S, Loftus EV Jr, Dubinsky MC, et al. Disease perceptions among people with Crohn's disease. Inflamm Bowel Dis. 2008; 14: 1097-1101.
53. Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res. 1996; 40: 503-509. (Pubitemid 26174492)
54. Shoor S, Lorig KR,. Self-care and the doctor-patient relationship. Med Care. 2002; 40 (4 Suppl): II40-44.
55. Andrews J, Mountifield RE, Van Langenberg DR, et al. Un-promoted issues in inflammatory bowel disease (IBD): opportunities to optimise care. Intern Med J. 2010; 40: 173-182.
56. Barrett SM, Standen PJ, Lee AS, et al. Personality, smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996; 8: 651-655. (Pubitemid 26241593)
57. Moser G, Tillinger W, Sachs G, et al. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1995; 7: 853-858.
58. Lewis M,. Attributions and inflammatory bowel disease: patients' perceptions of their ilness causes and effects of these perceptions on relationships. AARN News Letter. Vol. 161998.
59. Kiebles JL, Doerfler B, Keefer L,. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16: 1685-1695.
60. Mussell M, Bocker U, Nagel N, et al. Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand J Gastroenterol. 2003; 38: 755-762. (Pubitemid 36920498)
61. Schwarz SP, Blanchard EB,. Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther. 1991; 29: 167-177.
62. Miehsler W, Weichselberger M, Offerlbauer-Ernst A, et al. Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis. 2008; 14: 1273-1280.
63. Kane S,. IBD Self Management: The AGA Guide to Crohn's Disease and Ulcerative Colitis. AGA Press; 2010.
64. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010; 16: 112-124.
65. Saghaei M,. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004; 4: 26.
66. Lorig KR, Ritter PL, Dost A, et al. The Expert Patients Programme online, a 1-year study of an Internet-based self-management programme for people with long-term conditions. Chronic Ill. 2008; 4: 247-256.
67. Lorig KR, Holman H,. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003; 26: 1-7.
68. Marks R, Allegrante JP, Lorig K,. A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (part II). Health Promot Pract. 2005; 6: 148-156.
69. Levenstein S, Prantera C, Varvo V, et al. Development of the Perceived Stress Questionnaire: a new tool for psychosomatic research. J Psychosom Res. 1993; 37: 19-32. (Pubitemid 23040175)
70. Levenstein S, Prantera C, Varvo V, et al Development of the perceived stress questionnaire: a new tool for psychosomatic research. J Psychosom Res. 1993; 37: 19-32. (Pubitemid 23040175)
71. Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol. 2000; 95: 1213-1219.
72. Morisky D, Green, LW, Levine, DM,. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24: 67-74. (Pubitemid 16125389)
73. Irvine E,. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality of life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999; 28: S23-27. (Pubitemid 30349263)
74. Lorig K, Ritter PL, Villa FJ, et al. Community-based peer-led diabetes self-management: a randomized trial. Diabetes Educ. 2009; 35: 641-651.
75. Lorig K, Ritter PL, Plant K,. A disease-specific self-help program compared with a generalized chronic disease self-help program for arthritis patients. Arthritis Rheum. 2005; 53: 950-957. (Pubitemid 41811137)
76. Farrell K, Wicks MN, Martin JC,. Chronic disease self-management improved with enhanced self-efficacy. Clin Nurs Res. 2004; 13: 289-308. (Pubitemid 39434254)
77. Bandura A,. Health promotion by social cognitive means. Health Educ Behav. 2004; 31: 143-164. (Pubitemid 38569365)
78. Bandura A,. Social cognitive theory: an agentic perspective. Annu Rev Psychol. 2001; 52: 1-26. (Pubitemid 33705565)
79. Kennedy AP, Nelson E, Reeves D, et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut. 2004; 53: 1639-1645. (Pubitemid 39434108)
80. Kennedy A, Nelson E, Reeves D, et al. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol Assess. 2003; 7: iii, 1- 113.
81. Barlow C, Cooke D, Mulligan K, et al. A critical review of self-management and educational interventions in inflammatory bowel disease. Gastroenterol Nurs. 2010; 33: 11-18.
82. Keefer L, Kiebles JL, Martinovich Z, et al. Behavioral interventions may prolong remission in patients with inflammatory bowel disease. Behav Res Ther. 2010 [Epub ahead of print].
83. Keefer L, Kiebles J, Kwiatek M, et al. The effect of gut-directed hypnotherapy on ulcerative colitis: preliminary results from the Ulcerative Colitis Relapse Prevention Trial (UCRPT). Biol Res Nurs. 2011 [Epub ahead of print].
84. Lorig KR, Ritter PL, Laurent DD, et al. Internet-based chronic disease self-management: a randomized trial. Med Care. 2006; 44: 964-971. (Pubitemid 44674028)